Aptevo Net Debt vs Total Assets Analysis

APVO Stock

USD 0.24 0.03 11.11%

Aptevo Therapeutics financial indicator trend analysis is way more than just evaluating Aptevo Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aptevo Therapeutics is a good investment. Please check the relationship between Aptevo Therapeutics Net Debt and its Total Assets accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.

Net Debt vs Total Assets

Net Debt vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aptevo Therapeutics Net Debt account and Total Assets. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Aptevo Therapeutics' Net Debt and Total Assets is 0.46. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Total Assets in the same time period over historical financial statements of Aptevo Therapeutics, assuming nothing else is changed. The correlation between historical values of Aptevo Therapeutics' Net Debt and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Aptevo Therapeutics are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Net Debt i.e., Aptevo Therapeutics' Net Debt and Total Assets go up and down completely randomly.

Correlation Coefficient

0.46

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Total Assets

Total assets refers to the total amount of Aptevo Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Aptevo Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Most indicators from Aptevo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aptevo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.At this time, Aptevo Therapeutics' Selling General Administrative is very stable compared to the past year. As of the 14th of November 2024, Sales General And Administrative To Revenue is likely to grow to 4.21, while Discontinued Operations is likely to drop about 866.1 K.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	33.7M	31.8M	28.3M	41.7M
Cost Of Revenue	19.0M	901K	567K	538.7K

Total Operating Expenses Cost Of Revenue

Aptevo Therapeutics fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Common Stock Shares Outstanding		-0.8	0.0	-0.51	-0.64	0.52	-0.2	0.4	-0.35	-0.4	-0.56	-0.64	0.34	-0.58	-0.04	-0.48	-0.18	-0.56	-0.46	0.58	-0.48	0.86	-0.42	-0.4	-0.52	-0.48
Total Assets	-0.8		-0.34	0.27	0.95	-0.65	0.28	-0.72	0.59	0.46	0.43	0.67	-0.7	0.86	-0.16	0.74	-0.15	0.8	0.77	-0.88	0.1	-0.77	0.4	0.01	0.83	0.79
Other Current Liab	0.0	-0.34		0.43	-0.57	0.18	0.1	0.36	-0.39	-0.18	0.27	-0.39	0.62	-0.63	0.69	-0.57	0.76	-0.55	-0.28	0.6	0.78	-0.06	0.42	0.49	-0.61	-0.65
Total Current Liabilities	-0.51	0.27	0.43		0.03	0.01	-0.22	-0.08	0.08	0.17	0.18	0.39	0.03	0.16	0.04	0.21	0.1	0.2	-0.1	-0.12	0.78	-0.59	0.16	0.64	0.09	0.08
Total Stockholder Equity	-0.64	0.95	-0.57	0.03		-0.61	0.25	-0.72	0.65	0.44	0.29	0.63	-0.82	0.92	-0.32	0.79	-0.36	0.84	0.79	-0.93	-0.2	-0.58	0.23	-0.2	0.89	0.87
Other Liab	0.52	-0.65	0.18	0.01	-0.61		-0.63	0.42	-0.14	-0.42	-0.75	-0.55	0.45	-0.42	-0.12	-0.48	-0.15	-0.25	-0.9	0.47	-0.09	0.45	-0.53	-0.21	-0.37	-0.27
Net Tangible Assets	-0.2	0.28	0.1	-0.22	0.25	-0.63		0.18	-0.38	0.59	0.83	0.03	-0.25	-0.14	0.7	-0.21	0.37	-0.29	0.65	0.07	0.07	-0.04	0.82	-0.04	-0.19	-0.26
Property Plant And Equipment Net	0.4	-0.72	0.36	-0.08	-0.72	0.42	0.18		-0.64	0.23	0.11	-0.34	0.34	-0.79	0.44	-0.79	0.19	-0.78	-0.51	0.79	0.06	0.6	0.0	0.22	-0.84	-0.82
Current Deferred Revenue	-0.35	0.59	-0.39	0.08	0.65	-0.14	-0.38	-0.64		0.1	-0.19	0.55	-0.62	0.8	-0.67	0.72	-0.47	0.87	0.36	-0.82	-0.24	-0.35	-0.29	0.02	0.84	0.84
Net Debt	-0.4	0.46	-0.18	0.17	0.44	-0.42	0.59	0.23	0.1		0.67	0.61	-0.7	0.28	0.15	0.18	-0.18	0.2	0.51	-0.3	0.01	-0.21	0.41	0.24	0.17	0.12
Retained Earnings	-0.56	0.43	0.27	0.18	0.29	-0.75	0.83	0.11	-0.19	0.67		0.39	-0.24	0.0	0.61	-0.03	0.49	-0.11	0.65	-0.06	0.44	-0.41	0.81	0.47	-0.08	-0.18
Accounts Payable	-0.64	0.67	-0.39	0.39	0.63	-0.55	0.03	-0.34	0.55	0.61	0.39		-0.65	0.71	-0.41	0.72	-0.3	0.65	0.53	-0.73	0.09	-0.59	0.06	0.49	0.61	0.57
Cash	0.34	-0.7	0.62	0.03	-0.82	0.45	-0.25	0.34	-0.62	-0.7	-0.24	-0.65		-0.77	0.41	-0.66	0.65	-0.68	-0.68	0.76	0.43	0.19	-0.02	0.16	-0.72	-0.69
Non Current Assets Total	-0.58	0.86	-0.63	0.16	0.92	-0.42	-0.14	-0.79	0.8	0.28	0.0	0.71	-0.77		-0.63	0.93	-0.54	0.97	0.56	-0.98	-0.22	-0.58	-0.1	-0.12	0.99	0.98
Cash And Short Term Investments	-0.04	-0.16	0.69	0.04	-0.32	-0.12	0.7	0.44	-0.67	0.15	0.61	-0.41	0.41	-0.63		-0.71	0.8	-0.67	0.08	0.57	0.53	-0.01	0.81	0.16	-0.66	-0.69
Net Receivables	-0.48	0.74	-0.57	0.21	0.79	-0.48	-0.21	-0.79	0.72	0.18	-0.03	0.72	-0.66	0.93	-0.71		-0.55	0.89	0.51	-0.91	-0.19	-0.53	-0.2	-0.04	0.92	0.89
Non Current Liabilities Total	-0.18	-0.15	0.76	0.1	-0.36	-0.15	0.37	0.19	-0.47	-0.18	0.49	-0.3	0.65	-0.54	0.8	-0.55		-0.51	-0.02	0.47	0.69	-0.26	0.64	0.38	-0.53	-0.57
Inventory	-0.56	0.8	-0.55	0.2	0.84	-0.25	-0.29	-0.78	0.87	0.2	-0.11	0.65	-0.68	0.97	-0.67	0.89	-0.51		0.42	-0.95	-0.17	-0.6	-0.19	-0.11	0.98	0.98
Other Current Assets	-0.46	0.77	-0.28	-0.1	0.79	-0.9	0.65	-0.51	0.36	0.51	0.65	0.53	-0.68	0.56	0.08	0.51	-0.02	0.42		-0.63	-0.09	-0.4	0.55	0.0	0.53	0.45
Other Stockholder Equity	0.58	-0.88	0.6	-0.12	-0.93	0.47	0.07	0.79	-0.82	-0.3	-0.06	-0.73	0.76	-0.98	0.57	-0.91	0.47	-0.95	-0.63		0.21	0.59	0.01	0.09	-0.97	-0.95
Total Liab	-0.48	0.1	0.78	0.78	-0.2	-0.09	0.07	0.06	-0.24	0.01	0.44	0.09	0.43	-0.22	0.53	-0.19	0.69	-0.17	-0.09	0.21		-0.59	0.52	0.7	-0.27	-0.3
Property Plant And Equipment Gross	0.86	-0.77	-0.06	-0.59	-0.58	0.45	-0.04	0.6	-0.35	-0.21	-0.41	-0.59	0.19	-0.58	-0.01	-0.53	-0.26	-0.6	-0.4	0.59	-0.59		-0.41	-0.37	-0.54	-0.51
Total Current Assets	-0.42	0.4	0.42	0.16	0.23	-0.53	0.82	0.0	-0.29	0.41	0.81	0.06	-0.02	-0.1	0.81	-0.2	0.64	-0.19	0.55	0.01	0.52	-0.41		0.18	-0.15	-0.21
Short Term Debt	-0.4	0.01	0.49	0.64	-0.2	-0.21	-0.04	0.22	0.02	0.24	0.47	0.49	0.16	-0.12	0.16	-0.04	0.38	-0.11	0.0	0.09	0.7	-0.37	0.18		-0.2	-0.25
Intangible Assets	-0.52	0.83	-0.61	0.09	0.89	-0.37	-0.19	-0.84	0.84	0.17	-0.08	0.61	-0.72	0.99	-0.66	0.92	-0.53	0.98	0.53	-0.97	-0.27	-0.54	-0.15	-0.2		0.99
Common Stock	-0.48	0.79	-0.65	0.08	0.87	-0.27	-0.26	-0.82	0.84	0.12	-0.18	0.57	-0.69	0.98	-0.69	0.89	-0.57	0.98	0.45	-0.95	-0.3	-0.51	-0.21	-0.25	0.99

Click cells to compare fundamentals

Aptevo Therapeutics Account Relationship Matchups

Aptevo Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	66.3K	77.1K	106.5K	116.0K	278.1K	292.0K
Total Assets	53.4M	53.5M	56.6M	34.2M	24.8M	23.6M
Other Current Liab	9.1M	9.5M	23.1M	6.7M	3.2M	3.1M
Total Current Liabilities	38.2M	14.5M	34.8M	8.7M	7.2M	6.9M
Total Stockholder Equity	11.8M	16.6M	1.2M	18.0M	12.2M	11.6M
Net Tangible Assets	7.4M	16.6M	1.2M	18.0M	16.2M	18.4M
Property Plant And Equipment Net	7.7M	5.5M	4.0M	6.8M	5.8M	5.9M
Net Debt	10.7M	(12.6M)	(28.3M)	(13.1M)	(11.5M)	(10.9M)
Retained Earnings	(167.9M)	(185.6M)	(214.1M)	(206.0M)	(223.4M)	(234.6M)
Accounts Payable	13.0M	5.6M	3.5M	3.5M	4.0M	6.5M
Cash	12.4M	40.0M	45.0M	22.6M	16.9M	21.2M
Non Current Assets Total	23.4M	6.3M	4.0M	6.8M	5.8M	5.5M
Cash And Short Term Investments	12.4M	40.0M	45.0M	22.6M	16.9M	16.1M
Net Receivables	7.0M	2.4M	3.7M	2.5M	2.3M	4.5M
Liabilities And Stockholders Equity	53.4M	53.5M	56.6M	34.2M	24.8M	23.6M
Non Current Liabilities Total	3.3M	22.4M	20.6M	7.5M	5.4M	5.1M
Inventory	6.1M	4.8M	3.1M	1.6M	1.4M	1.3M
Other Current Assets	160K	133K	780K	744K	2.2M	2.3M
Other Stockholder Equity	179.7M	202.2M	215.2M	224.0M	235.6M	166.4M
Total Liab	41.6M	37.0M	55.4M	16.2M	12.6M	12.0M
Property Plant And Equipment Gross	7.7M	2.8M	4.0M	19.8M	19.4M	20.3M
Total Current Assets	30.0M	47.3M	52.6M	27.5M	19.1M	37.5M
Common Stock	45K	46K	47K	48K	61K	58.0K
Property Plant Equipment	7.7M	5.5M	4.0M	6.8M	7.8M	5.9M
Non Currrent Assets Other	11.3M	746K	68K	(6.8M)	(6.1M)	(5.8M)
Other Assets	8.4M	11.3M	3.5M	68K	61.2K	58.1K
Short Long Term Debt Total	23.2M	27.4M	16.7M	9.5M	5.4M	5.1M
Common Stock Total Equity	22K	23K	45K	46K	52.9K	34.3K
Non Current Liabilities Other	734K	200K	3.3M	15.6M	17.9M	18.8M
Net Invested Capital	31.7M	41.6M	16.6M	21.4M	12.2M	11.6M

Pair Trading with Aptevo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Aptevo Stock

0.77	VALN	Valneva SE ADR	Pair Corr
0.65	VANI	Vivani Medical	Pair Corr

Moving against Aptevo Stock

0.64	DMAC	DiaMedica Therapeutics	Pair Corr
0.62	DOMH	Dominari Holdings	Pair Corr
0.61	DNLI	Denali Therapeutics	Pair Corr
0.43	VCYT	Veracyte	Pair Corr
0.41	VERA	Vera Therapeutics	Pair Corr

The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.

The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock:

How To Invest In Aptevo

Details

Is Aptevo Stock a good investment?

Details

What is Aptevo Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aptevo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.

You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.24)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.73)

Return On Equity

(2.51)

The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aptevo Net Debt vs Total Assets Analysis

Net Debt vs Total Assets

Net Debt vs Total Assets Correlation Analysis

Correlation Coefficient

Net Debt

Total Assets

Aptevo Therapeutics fundamental ratios Correlations

Aptevo Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aptevo Therapeutics fundamental ratios Accounts

Pair Trading with Aptevo Therapeutics

Moving together with Aptevo Stock

Moving against Aptevo Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Intangible Assets	+ 0.99	Non Current Assets Total
Common Stock	+ 0.99	Intangible Assets
Common Stock	+ 0.98	Non Current Assets Total
Intangible Assets	+ 0.98	Inventory
Common Stock	+ 0.98	Inventory
Inventory	+ 0.97	Non Current Assets Total

Other Stockholder Equity	- 0.98	Non Current Assets Total
Intangible Assets	- 0.97	Other Stockholder Equity
Common Stock	- 0.95	Other Stockholder Equity
Other Stockholder Equity	- 0.95	Inventory
Other Stockholder Equity	- 0.93	Total Stockholder Equity
Other Stockholder Equity	- 0.91	Net Receivables